Reported results
- Total company revenues were $524.4 million for the third quarter of 2026.
- BRINSUPRI revenues were $400.1 million for the third quarter of 2026.
- ARIKAYCE revenues were $124.4 million for the third quarter of 2026.
- Net loss was $100.3 million, or $0.46 per share, for the third quarter of 2026.
- Research and development (R&D) expenses were $270.0 million for the third quarter of 2026.
- Selling, general and administrative (SG&A) expenses were $253.0 million for the third quarter of 2026.
Guidance
- 2026 BRINSUPRI revenue guidance: $1.35 billion to $1.4 billion
- 2026 ARIKAYCE revenue guidance: $460 million to $470 million
Price and volatility reaction
The stock moved +15.1% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -31.9 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 96.98 | 2026-10-28 |
| Close after release | 111.59 | 2026-10-29 |
| Realised move | +15.1% | close to close |
| 30d ATM IV change | -31.9 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.
